logo
Plus   Neg
Share
Email

Atara To Suspend Development Of PINTA 745 As Trial Fails To Meet Primary Goal

Atara Biotherapeutics, Inc. (ATRA) Monday said its Phase 2 proof-of-concept clinical trial for PINTA 745 for the treatment of protein energy wasting or PEW in patients with end stage renal disease or ESRD did not meet its primary endpoint.

The primary endpoint is defined as the percent change from baseline in Lean Body Mass as measured by Dual Energy X-Ray Absorptiometry at week 12 following weekly treatment with PINTA 745.

PINTA 745 also did not improve physical function, measures of glycemic control and markers of inflammation. There were no treatment related serious adverse events observed in the trial.

Atara Bio will now suspend further development of PINTA 745. To date, third-party direct costs for the development of PINTA 745 from inception through the third quarter of 2015 were about $10 million.

For comments and feedback contact: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Amazon Inc. is leading a new $575 million investment in British food delivery company Deliveroo, intensifying the e-commerce giant's competition with rival Uber and its Uber Eats service. Deliveroo noted that Amazon is set to be the largest investor in the Series G preferred shared funding round. With the latest funding round, Deliveroo has raised $1.53 billion. While reporting financial results for the first quarter on Friday, Deere & Co. (DE) slashed its earnings and revenue growth guidance for the full-year 2019. The company said the lower forecast is partly a result of actions taken by it to prudently manage field inventories, which will cause production... European Union regulators on Thursday fined five global banks a total of 1.07 billion euros, or $1.2 billion, for participating in foreign exchange spot trading cartels and manipulating the foreign-exchange currency market. The five banks are Barclays, Royal Bank of Scotland, Citigroup, JPMorgan Chase and Japan's MUFG Bank, formerly known as Bank of Tokyo-Mitsubishi.
Follow RTT